About the Company
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company that is involved in the development of cell and gene therapies for life-threatening rare genetic diseases. Abeona Therapeutics Inc. leads various programs inclusive of EB - 101 for recessive dystrophic epidermolysis bullosa, ABO - 102, and an Adeno associated virus-based gene therapy for Sanfilippo syndrome type A. Its research especially focuses on the development of treatments of rare diseases using gene therapy and human plasma-derived therapeutics. The company was initially known as Access Pharmaceuticals and was based in Dallas, established in the year 1989. It is a company that is at the forefront of the rapidly advanced fields of genetic medicine. Currently, the company is situated in New York, United States of America, and is listed on the NASDAQ as ABEO. Under the robust pipeline of the company, there lies a fully operational manufacturing facility producing therapies and vectors for clinical and preclinical studies. Abeona Therapeutics Inc. is also concentrating on developing the AIM Vector PLatform targeting a wide range of organs and multiple route deliveries for gene therapy.;
Organisation | Abeona Therapeutics Inc |